Oct-6 CRISPR Activation Plasmid (h): sc-401826-ACT

POU3F1 (Oct-6) encodes a POU-domain transcription factor that regulates lineage specification and differentiation programs, with prominent roles in neural crest–derived cells and Schwann cell development. Oct-6 modulates transcriptional networks controlling cell cycle exit, myelination-associated gene expression, and developmental timing through promoter/enhancer binding and cooperation with other transcriptional regulators. Dysregulated POU3F1 activity has been linked to aberrant differentiation states and altered proliferative capacity, making it relevant for studies of neurodevelopmental pathways, glial biology, and transcription factor–driven cellular plasticity. In human cell models, Oct-6 serves as a node for interrogating gene regulatory circuitry underlying fate decisions and stress-responsive transcription.

Oct-6 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous POU3F1 expression without altering the underlying DNA sequence.

Oct-6 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the POU3F1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the POU3F1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Oct-6 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native POU3F1 locus and enabling the study of Oct-6-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Oct-6 pathway restoration in tumor cells with silenced or reduced POU3F1 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.